RxDoctor Payments Data

Armine Tadevosyan

Family · Encino, CANPI 1508488891

Payments from drug & device makers

$3,638in general payments, 2019–2025

Across 120 payments — averaging $30.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Lilly USA, LLC$470
  • Bayer$465
  • Ardelyx, Inc.$258
  • Sumitomo Pharma America, Inc.$182
  • AbbVie$174
  • plus $895 from 15 others

What the payments were for

  • Food & beverage$3,638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,638 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide337$347,311
Repatha SureclickEvolocumab294$190,517
TrulicityDulaglutide79$74,777
LinzessLinaclotide70$44,486
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate90$44,035
EliquisApixaban46$38,325
ProliaDenosumab19$32,206
VascepaIcosapent Ethyl77$30,272
JanuviaSitagliptin Phosphate40$28,722
OzempicSemaglutide26$28,267
FarxigaDapagliflozin Propanediol38$27,739
XareltoRivaroxaban40$23,172
Praluent PenAlirocumab44$22,375
MyrbetriqMirabegron39$22,062
JardianceEmpagliflozin30$21,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$470$422,089416 claims
PfizerEliquis, Premarin$62$48,60969 claims
Novo NordiskOzempic, Rybelsus$172$45,16437 claims
AbbVieLinzess$174$44,48670 claims
Boehringer IngelheimJardiance, Jentadueto$145$32,48251 claims
AmgenProlia$1,194$32,20619 claims
Johnson & JohnsonXarelto$25$23,17240 claims
Sumitomo Pharma America, Inc.Gemtesa$182$13,44826 claims
BayerKerendia$465$12,54720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →